Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
Classifica tra le azioni #25864
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Prezzo delle azioni
$1.21
Capitalizzazione di mercato
$45.55M
Variazione (1 giorno)
-2.43%
Variazione (1 anno)
-34.60%
Paese
US
Scambia Metagenomi, Inc. Common Stock (MGX)

Categoria

Rapporto P/S per Metagenomi, Inc. Common Stock (MGX)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Metagenomi, Inc. Common Stock, il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Metagenomi, Inc. Common Stock da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
11.28 -
US